FDA rebuffs GSK on Avodart for risk reduction
This article was originally published in Scrip
Executive Summary
A complete response letter from the US FDA has thrown cold water on GlaxoSmithKline's hopes of beefing up sales of Avodart (dutasteride) before patent expiry by extending the drug's use to reducing the risk of prostate cancer.